An interventional study of Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS) and Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months. in Obesity Prevention, sponsored by Harokopio University. Not yet recruiting at 7 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Harokopio University · Not applicable, Interventional, and Prevention
The BETTER4U (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) project, funded by the European Union, aims to address obesity through biologically and behaviourally tailored interventions. Obesity is a major public health issue influenced by genetic, metabolic, and lifestyle factors. Despite current weight management interventions, many individuals face challenges due to these varied influences. The BETTER4U project seeks to improve weight management by incorporating artificial intelligence (AI) and polygenic risk scores (PRS) to personalize interventions. The goal is to test the effectiveness of these personalized interventions in improving weight loss compared to standard care, using advanced monitoring tools and AI models.
The BETTER4ALL personalized intervention is a multicentre, open-label, parallel-group randomized controlled trial (RCT) involving seven study sites across Cyprus, France, Greece, Poland, Portugal, Spain, and Sweden. A total of 1,022 participants with overweight or obesity (BMI ≥ 25 kg/m²), aged 18-65 years, will be enrolled. Participants will be randomized into two groups: an intervention group receiving personalized lifestyle recommendations based on AI and PRS, and a control group receiving standard care recommendations. The intervention will last six months, followed by a six-month follow-up assessment.
The intervention's key aspects include wearable devices and a mobile application to monitor participants' behaviour, including physical activity, sleep, and eating habits. The intervention also integrates genetic, metabolic, and environmental data to provide tailored recommendations for weight loss. Participants' outcomes will be assessed regarding BMI, weight loss maintenance, changes in clinical biomarkers, body composition, and other lifestyle parameters.
This RCT will provide valuable insights into the effectiveness of personalized weight management strategies. AI-driven personalized recommendations and real-time monitoring represent a significant shift from traditional, one-size-fits-all approaches. The results of this study could offer a more effective and sustainable model for obesity management, particularly by accounting for individual genetic predispositions and lifestyle factors. Furthermore, by evaluating the impact of the intervention on a wide range of health outcomes, including biomarkers and psychosocial factors, the study will provide a comprehensive understanding of how personalized interventions can improve overall health and weight management.
In addition to contributing to the scientific understanding of obesity and its management, this project has the potential to influence public health strategies, offering a more personalized, data-driven approach to obesity prevention and treatment. By integrating genetic, environmental, and lifestyle factors, the BETTER4U intervention could pave the way for future innovations in digital health and obesity management.
Obesity is a major global public health issue with significant physical, psychosocial, and financial implications, especially in vulnerable populations. It results from complex interactions between genetic, metabolic, lifestyle (e.g., diet, physical activity, sleep), psychological, and sociodemographic factors. Individual responses to weight management interventions vary considerably, necessitating personalized strategies to prevent and treat obesity. Data from clinical trials have demonstrated that response to weight loss treatments is considerably characterized by an inter-individual variation, resulting from a combination of multiple genetic and phenotypic factors, interacting in a non-linear manner. Thus, a tailor-made, evidence-based weight loss intervention is considered to be the optimal solution for obesity management. Modern technology and the use of artificial intelligence (AI) models provide the potential to individualize weight management by including more information about an individual before delivering a treatment plan, in a way that has not been possible before.
Recently, the European Commission (EC) funded the large-scale BETTER4U project (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) to improve weight management through a tailor-made intervention using AI. The project consortium consists of 28 partners across Europe, Israel, and Australia, including health and technology scientists, legal and communication experts, and representatives from the European Association for the Study of obesity, EASO.
The BETTER4U project started in November 2023 and will run until October 2027, having the potential to produce new knowledge on weight management in an adult population. In addition, the envisioned privacy-respecting BETTER4U platform will be capable for detailed behavioural monitoring, will provide an infrastructure for continued and widespread use of real-world data beyond the end of the project, using real-world data for understanding the contextual circumstances and health status, as a valuable clinical research and patient management tool.
The BETTER4U work plan is broken down into 9 work packages (WPs) and its methodology is orchestrated in 4 phases, namely: Phase 1: identification of all weight-gain related determinants; Phase 2: creation of an AI-based causal model; Phase 3: pilot and randomized controlled trials (RCT) for the creation of the BETTER4U integrated methodology; and Phase 4: communication and dissemination of the methodology.
The study will be implemented in seven intervention sites (Cyprus, France, Greece, Poland, Portugal, Spain, Sweden). The overall aim of this study is to assess the effectiveness of the personalized intervention on weight loss over six months, as well as evaluate its impact on other lifestyle parameters, clinical indices, and biomarkers, while also assessing the maintenance of weight loss over a follow-up period of another six months.
The intervention will be mainly delivered by dietitians/nutritionists and potentially other health professionals experienced in delivering interventions that target nutrition, physical activity, and other lifestyle parameters modification (called "implementers" hereinafter). In all cases, a certified dietitian/nutritionist should always supervise the intervention delivery. A centralized training will be provided by HUA (WP7 leader) in English to train study sites' representatives/research team on how to deliver the intervention (both for the intervention and the control groups). Then, using the train-the-trainer approach, each site's responsible representatives/research team will train in either English or the local language all the site implementers before initiating the recruitment of study participants. AUTH, UBERN, WINGS, and HUA technical partners will support the training on the use of the intervention tools. These include the BETTER4U App and Intervention Platform (WP6 tools), incorporating the causal AI model developed in WP5 and the monitoring tools that will allow the successful calculation of the BETTER4U Core Behaviour Indicators and Living Environment Indicators (BCBIs and LEIs) developed within WP6.
Overall, during the BETTER4All Personalized Intervention, there will be three types of data collected:
In-App data: these data will be the ones collected regularly via the BETTER4U App by the participants, either passively and unobtrusively (i.e. the BCBIs and LEIs) or actively by taking meal photos (e.g. via the Go Food functionality) and answering related questions on meal type (breakfast/ lunch/ dinner), food/ drink type/ content (fish, meat, pasta, alcohol etc.), as well as perception of appetite at the time of meal consumption. Details to be provided in SOP to describe use of the app and what the Go Food is, how to take photos, the questions accompanying this process, etc.
Online data reported through RedCap: these data will be the questionnaires answered by the participants online via RedCap at each visit, either on site during the visit or online for a period of ± one week from the visit.
Anthropometric and blood pressure measurements and biological samples collection: these data include measurements of body weight, waist circumference, body composition and blood pressure that will be conducted during the in-person visits, i.e. V2, V4, V5, as well as the blood and stool samples collection that will be repeated at V4. For all measurements, the same procedures as in V0 will be followed based on the relevant SOPs. Anthropometric and blood pressure measurements will be recorded on the Participant Evaluation Form.
Participants will also receive a structured counselling session, based on the evidence for psychosocial behavior change techniques, which may be characteristic of effective weight change interventions. The choice of the effective behavior change techniques was also based on Group Lifestyle Balance approach.
After the completion of the 6-month intervention period, the end-of-study visit (V4) will be scheduled. During this visit, participants will receive the final counselling session and will be asked to complete the end-of-study measurements and questionnaires. They will also be reminded that an additional follow-up visit after another 6 months will take place (i.e., V5 - 6-month follow-up visit). In the meantime, they will be advised to maintain the lifestyle changes that have been achieved, taking advantage of the counselling they received in the previous period, as well as to continue using the digital tools (wearable, App) and monitoring their lifestyle behaviours.
During the 6-month follow-up visit (V5), participants will return the wearables to the research team and will be asked to repeat the completion of questionnaires and measurements to evaluate the maintenance of potential improved behaviours and weight loss achieved during the intervention period.
After the end of the total 6-month intervention period for the last participant, each implementer will be asked to complete three questionnaires assessing the acceptability, feasibility, and appropriateness of the intervention. This will allow a first exploratory assessment of the three key implementation outcome measures, assessing stakeholders' perceptions of the intervention and the implementation strategies. The three questionnaires are the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).
The personal smartphone Android devices of each participant will be used, and participants will be provided with access to the deployed mobile App. More specifically, the mobile device will have the following functions:
It will act as the equipment hub for the connection of the BETTER4U smartwatches, locally collecting the generated data through Bluetooth technology, and, whenever possible, locally calculating relevant behavioural indicators. The device will act as a data collection tool itself, used for the collection of IMU-sensor data (i.e., accelerometer) and geolocation data (e.g., used for urban and socioeconomic context analytics, assessment of users' mobility and physical activity). It will act as the means of self-reported data collection from the participant, with repeated, episodic questions being communicated and answered through the smartphone device.
It will act as the means of photograph taking of meal occasions (including foods, drinks, etc.).
Through the app, it will serve as a snapshot of the users' collected data, showcasing some of their key indicators that can be computed directly on the device.
The wearable devices (smartwatches) to be used are going to be bought off-the-shelf devices, which will act as a passive monitoring tool and collect data from the following data sources:
Raw Data: Accelerometer Data (3-channel, 25Hz sampling rate) Readily Available Data: Stress Data (1 sample/minute), Heart Rate Variability (1 sample/minute), Steps Count (1 sample/minute), Sleep Structure (sleep duration, sleep stage duration), Calories Burned (1 sample/minute), SpO2 (1 sample/minute).
The smartwatch device data will be synced frequently with the user's smartphone, utilizing the Bluetooth Low Energy (BLE) protocol. Then they will be transferred to the BETTER4U servers, where the derived data calculation will take place. Extensive signal processing and AI/ML algorithms are used to derive meaningful information from the acquired signals, such as:
The BETTER4U Intervention Platform will act as an interface that facilitates the interactions between implementers and the AI model, by operating conjointly with the back-end services developed in WP5, to produce individualized guidelines for the management and prevention of weight gain. Furthermore, the web application will act as a tool that enables implementers to have a closer look at the behaviour of study participants by providing a detailed breakdown of the extracted indicators and how they evolve over time; thus, allowing for an on-the-fly assessment of the suggested individualized intervention scheme and a measurement of compliance.
53 studies on the registry are indexed under Genetic Risk Score; 35 are open to participants now.
This study's planned enrollment of 1,022 is above the median of 650 across 25 interventional studies indexed under Genetic Risk Score.
Browse Genetic Risk Score studies →Harokopio University is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive feedback and counselling from the implementers on their weight status and lifestyle behaviours, based on their measurements/responses during screening assessment. This counselling will be based on the general "healthy eating" (based on the Mediterranean diet) and "healthy lifestyle" recommendations for physical activity, sedentary time and sleep (based on WHO recommendations) and will be considered the "standard care". Those recommendations will also be handed in to them in the form of a "standard care leaflet" to take home. Participants will also be provided with a "standard hypocaloric diet" based on their needs for weight loss, aiming for a ≥ 5% reduction in body weight at the end of the 6-month intervention period. Participants in both the intervention and the control groups will be provided with the wearable (a smartwatch) which will be Bluetooth-paired with their personal smartphone.
Behavioral: Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.
Participants will receive personalized recommendations from implementers via the Better4U Intervention Platform, based on the AI model and, where available, the participant's PRS and genetic data. Inclusion of genetic information depends on the timing of recruitment, as genotyping results rely on the shipment and analysis timeline at Bioclinica. To ensure this data is incorporated, baseline visits should be scheduled once blood test results are available or expected within 1.5 months. Participants will also receive a structured counselling session based on the Transtheoretical Model (TTM), which assesses readiness to change across six stages. Participants will also receive a personalized hypocaloric diet tailored to support ≥5% weight loss over the 6-month intervention. All participants (intervention and control) will receive a smartwatch, paired via Bluetooth with their smartphone, along with detailed instructions and training on using the device and the BETTER4U App.
Behavioral: Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS)
Personalized lifestyle intervention that integrates artificial intelligence (AI), polygenic risk scores (PRS), and real-time behavioral and environmental data. MyBETTER4U dynamically adapts to individual needs by combining genetic and biological profiling (e.g., PRS, microbiome, metabolomics), behavioral determinants (e.g., eating habits, physical activity, sleep patterns), sociodemographic and environmental context, technology-assisted self-monitoring through wearable devices and digital tools, and AI-driven decision-support systems that generate ongoing, individualized recommendations. Intervention group participants will receive personalized recommendations via the Better4U Platform, based on the AI model and, when available, their PRS and genetic data. Since genotyping results depend on sample processing timelines, baseline visits should be scheduled when results are available or expected within 1.5 months to ensure inclusion in the next visit.
Participants will receive feedback and counselling from the implementers on their weight status and lifestyle behaviours, based on their measurements/responses during the screening assessment. This counselling will be based on the general "healthy eating" (based on the Mediterranean diet) and "healthy lifestyle" recommendations for physical activity, sedentary time, and sleep (based on WHO recommendations) and will be considered the "standard care". Those recommendations will also be handed in to them in the form of a "standard care leaflet" to take home. Participants will also be provided with a "standard hypocaloric diet" based on their needs for weight loss, aiming for a ≥ 5% reduction in body weight at the end of the 6-month intervention period.
Mean change in BMI
The primary outcome measure will be the mean change in BMI (in kg/m2) from baseline at the end of the 6-month intervention period between the intervention and the control group.
Time frame: Baseline (prior to intervention) Midpoint (3 months - for psychosocial parameters) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Percentage of participants achieving a ≥ 5% reduction in body weight
Percentage of those achieving a ≥ 5% reduction in body weight at the end of the 6-month intervention period in the intervention vs the control group.
Time frame: Baseline (prior to intervention) Follow-up (12 months from baseline / 6 months post-intervention)
Percentage of weight loss maintenance
Percentage of weight loss maintenance from the end of the 6-month intervention period until the 6-month follow-up assessment in the intervention vs the control group (assessed as a relative percent of the achieved weight loss at the end of the 6-month intervention).
Time frame: End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Mean change in systolic and diastolic blood pressure
Mean change in systolic and diastolic blood pressure (in mmHg) from baseline at the end of the 6-month intervention period and after a 6-month follow-up assessment in the intervention vs the control group.
Time frame: Baseline (prior to intervention) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Modifications in metabolomic, lipidomic biomarkers, adikokines, cardiometabolic and inflammatory biomarkers, as well as in gut microbiota
Modifications in metabolomic, lipidomic biomarkers, adipokines, cardiometabolic and inflammatory biomarkers, as well as in gut microbiota at the end of the 6-month intervention period compared to baseline.
Time frame: Baseline (prior to intervention) End of intervention (6 months)
Improvements in other lifestyle parameters and overall quality of life
Improvements in other lifestyle (i.e. physical activity, sleep, eating habits) and overall quality of life in the middle and at the end of the 6-month intervention period, as well as after a 6-month follow-up assessment in the intervention vs the control group.
Time frame: Baseline (prior to intervention) Midpoint (3 months - for psychosocial parameters) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Improvements in parameters that modulate eating behaviour
Improvements in parameters that modulate eating behaviour from baseline at the end of the 6-month intervention period, as well as after a 6-month follow-up assessment in the intervention vs the control group - to be further described.
Time frame: Baseline (prior to intervention) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Modifications in body composition
Mean change in percentage of fat mass and fat-free mass, as well as in kg of fat mass and fat-free mass from baseline at the end of the 6-month intervention period and after a 6-month follow-up assessment in the intervention vs the control group.
Time frame: Baseline (prior to intervention) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Improvements in psychosocial parameters
Improvements in psychosocial parameters (i.e. anxiety, depression, self-regulation, motivation factors, emotion regulation factors) in the middle and at the end of the 6-month intervention period, as well as after a 6-month follow-up assessment in the intervention vs the control group.
Time frame: Baseline (prior to intervention) Midpoint (3 months - for psychosocial parameters) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Mean change in BMI of offspring/extended family environment of study participants
Mean change in BMI (in kg/m2) of offspring/extended family environment (i.e. in wife/husband and/or children) of study participants from baseline at the end of the 6-month intervention period, as well as after a 6-month follow-up assessment.
Time frame: Baseline (prior to intervention) End of intervention (6 months) Follow-up (12 months from baseline / 6 months post-intervention)
Plan to share: Undecided
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harokopio University